title: Increased dermal perfusion after skin burn injury by D-myo-inositol-1,2,6-trisphosphate.
abstract: Full-thickness burn injury results in a continuous deterioration of blood flow due to vascular sludging, thrombosis formation and oedema leading to irreversible ischaemia and tissue necrosis. D-myo-inositol-1,2,6-trisphosphate (IP3) has previously been shown to reduce burn-induced oedema formation and inflammation involved in the pathophysiology of progressive ischaemia. A full-thickness burn injury (1 cm2) was induced in the abdominal skin of anaesthetized rats using an electrically heated thermoprobe. Blood flow in the experimental area was measured by laser Doppler flowmetry during 6.5 h postburn. The experiments included five groups. Three burned groups were treated intravenously with IP3 and received respectively: a bolus dose of 4 mg/kg followed by a continuous intravenous infusion of 20 mg/kg/h, 8 mg/kg + 40 mg/kg/h or 16 mg/kg + 60 mg/kg/h. One burned and one unburned control group received a corresponding bolus dose and infusion of saline. Results showed a significant inhibition of dermal ischaemia in the burned groups receiving IP3 at all dose intervals as compared to saline-treated burned rats (all P < 0.001). We conclude that IP3 improved local dermal perfusion in burned skin. Probable mechanisms of action could be the vasodilatory and anti-inflammatory properties of the agent.
authors.affiliation: Department of Plastic Surgery, Sahlgrenska University Hospital, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Tarnow
authors.forename: A
authors.initials: A
authors.lastname: Jönsson
authors.forename: G
authors.initials: G
authors.lastname: Rimbäck
authors.forename: J
authors.initials: J
authors.lastname: Cassuto
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002056:Burns / Q000188:drug therapy*; D004195:Disease Models, Animal; D007262:Infusions, Intravenous; D007295:Inositol Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow; D012867:Skin / Q000098:blood supply*; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007295:Inositol Phosphates; C059368:atrinositol